Science News from #ACC22
Top Late-Breaking Science from ACC 2022
AHA experts Amit Khera, MD, MSc, FAHA, Alanna Morris, MD, MSc, FAHA, Kathryn Lindley, MD, and Chiadi Ndumele, MD, PhD, MHS comment on some of the top late-breaking clinical trial science from ACC 2022.
Selected science from Saturday, April 2
2022 Guidelines for the Management of Heart Failure
Writing Group Chair Paul Heidenreich, MD, MS and Vice Chair Biykem Bozkurt, MD, PhD, FAHA, review some of the key changes reflected in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
Justin A. Ezekowitz | University of Alberta, Edmonton, Canada
CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension and Pregnancy Outcomes: A Pragmatic Multicenter RCT
Alan Tita | University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL
Also published on Saturday
FAME 3: Quality of Life After Fractional Flow Reserve-Guided PCI Compared with Coronary Bypass Surgery
William F. Fearon | Stanford University, Stanford, CA, et al.
Published in Circulation
Selected science from Sunday, April 3
IVVE: Randomized Controlled Trial Of Influenza Vaccine In Patients With Heart Failure To Reduce Adverse Vascular Events
Mark Loeb | McMaster University, Hamilton, Canada
Also published Sunday
TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol
Brian A. Bergmark | Brigham and Women's Hospital, Harvard Medical School, Boston, MA, et al.
Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial
Paolo Della Bella | San Raffaele University-Hospital, Milan, Italy, et al.
Selected science from Monday, April 4
POISE-3: The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery
Maura Marcucci | McMaster University, Hamilton, ON, Canada
Also published Monday
ADAPT-TAVR: Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial
Duk-Woo Park | University of Ulsan College of Medicine, Seoul, Korea, et al.
CHOCOLATE TOUCH: A Randomized Trial of Chocolate Touch Compared with Lutonix Drug-Coated Balloon in Femoropopliteal Lesions
Mehdi H. Shishehbor | University Hospitals Harrington Heart and Vascular Institute, Cleveland, OH, et al.